Atorvastatin-loaded peptide amphiphiles against corneal neovascularization.
Nanomedicine (Lond)
; 18(17): 1095-1108, 2023 07.
Article
em En
| MEDLINE
| ID: mdl-37610088
Corneal neovascularization is an eye disease that affects over 1 million people every year and can lead to blindness. It is caused by inflammation and the unwanted formation of blood vessels in the eye. Current treatments for this disease are not fully effective. Atorvastatin (ATV) is one drug that has been partially successful at treating corneal neovascularization, but it does not stay in the eye long enough and does not mix well with the water-based environment of the eye. To overcome this, ATV was combined with three specially designed nanocarriers. These nanocarriers were peptides, short stretches of protein. They were designed to be amphiphilic, meaning that one section is hydrophilic (literally meaning 'water loving') and one section is hydrophobic ('water hating'). These peptide nanocarriers allowed ATV to stay in the water-based environment of the eye longer. The peptide with the most hydrophobic chains (qC16-Tat47-57) was able to carry more ATV than the other peptides and produced particles of a desired shape. ATV-qC16-Tat47-57 nanocarriers were found to release slowly. These nanocarriers were also found to prevent the development of new blood vessels on a membrane in a hen's egg used to mimic the eye. There was also no sign of irritation on this membrane or in the eyes of New Zealand rabbits. These results show ATV-qC16-Tat47-57 has a prolonged therapeutic effect, prevents the formation of new blood vessels and is tolerated in the eye. ATV-qC16-Tat47-57 is therefore potentially a more effective alternative to ATV treatment alone.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neovascularização da Córnea
Limite:
Humans
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article